Francesco Maura, Associate Director of Myeloma Research Institute at the University of Miami, shared a post on X:
“Together with Ross Firestone and Saad Z. Usmani we are happy to share our thoughts on SUCCESSOR-2 clinical trial published few days ago on The Lancet”
Title: Will mezigdomide find its place in the T-cell redirecting treatment landscape for relapsed multiple myeloma?
Authors: Francesco M., Ross F., Saad Z. U.
Other articles featuring Dr. Maura on OncoDaily.